RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
TUCCI M
Collezione ASL Asti
Items : 56
Demoralization Syndrome in End-Of-Life Cancer Patients: A Qualitative Study. in The American journal of hospice & palliative care / Am J Hosp Palliat Care. 2024 Sep 6:10499091241274315. doi: 10.1177/10499091241274315.
2024
ASL Asti
AOU Città della Salute di Torino
Tucci M; Olivetti V; Botto R; Pidinchedda A; Cito AL; Bovero A; Geminiani GC;
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2024 Sep;27(3):385-392. doi: 10.1038/s41391-023-00775-y. Epub 2023 De
2024
ASL Asti
AO Ordine Mauriziano
Di Maio M; Tucci M; Vogl UM; Buttigliero C; Tombal B; Cathomas R; Smith MR; Fizazi K; Treglia G; Turco F; Gillessen S;
Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Oct;22(5):102138. doi: 10.1016/j.clgc.2024.102138. Epub 2024 Jun 12.
2024
ASL Asti
AOU San Luigi di Orbassano
AO Ordine Mauriziano
Tucci M; Scagliotti GV; Di Maio M; Palesandro E; Poletto S; Calabrese M; Saporita I; Crespi V; Farinea G; Di Stefano RF; Gallina A; Fossati N; Zilli T; Delcuratolo MD; Gillessen S; Turco F; Vogl UM; Buttigliero C;
Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects. in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2024 Mar 1;32(3):202. doi: 10.1007/s00520-024-08392-8.
2024
ASL Asti
AOU Alessandria
AO Ordine Mauriziano
Cinieri S; Comandone A; Airoldi M; Rossi M; Rossetti G; Lanzetta G; Cavanna L; Bossi P; Ibrahim T; De Giorgi U; Tucci M; Santini D; Fusco V; Di Maio M; Valsecchi AA;
Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials. in Cancer treatment reviews / Cancer Treat Rev. 2024 Jun;127:102745. doi: 10.1016/j.ctrv.2024.102745. Epub 2024 Apr 27.
2024
ASL Asti
Munoz F; Muraro M; Singh N; Campisi I; Palesandro E; Turco F; Buttigliero C; Durante E; Giuliani J; Tucci M; Mandarà M; Fiorica F;
Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey. in Tumori / Tumori. 2024 Jun;110(3):174-185. doi: 10.1177/03008916241236279. Epub 2024 Mar 10.
2024
ASL Asti
AOU Alessandria
AO Ordine Mauriziano
Cinieri S; Vignani F; Valsecchi AA; Fusco V; Dionisio R; De Giorgi U; Di Maio M; Santini D; Tucci M;
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies. in ESMO open / ESMO Open. 2024 Jul;9(7):103484. doi: 10.1016/j.esmoop.2024.103484. Epub 2024 Jun 19.
2024
AOU Alessandria
ASL Cuneo 2
AOU Città della Salute di Torino
ASL Asti
De Giorgi U; Santini D; Bertoldo F; Tucci M; Valsecchi AA; Procopio G; Berruti A; Di Maio M; Pantano F; Cursano MC;
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma. in Journal of clinical medicine / J Clin Med. 2024 Jan 5;13(2):307. doi: 10.3390/jcm13020307.
2024
ASL Asti
AOU San Luigi di Orbassano
Buttigliero C; Carfì FM; Tucci M; Calabrese M; Saporita I; Pisano C; Turco F; Delcuratolo MD; Di Stefano RF; Samuelly A;
TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma. in Pathologica / Pathologica. 2024 Feb;116(1):55-61. doi: 10.32074/1591-951X-937.
2024
ASL Asti
Milella M; Ascani S; Eccher A; Hattab IM; Pierconti F; Tucci M; Antonelli A; Veccia A; Cimadamore A; Martignoni G; Francesconi S; Caliò A; Munari E; Caserta C; Sirgiovanni G; Gobbo S; Malpeli G; Brunelli M; Buffoni L; Cheng L; Bracarda S;
Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis. in Cells / Cells. 2024 Aug 22;13(16):1396. doi: 10.3390/cells13161396.
2024
ASL Asti
AOU San Luigi di Orbassano
Tucci M; Di Stefano FR; Audisio M; Turco F; Delcuratolo MD; Poletto S; Saporita I; Carfì F; Calabrese M; Farinea G; Buttigliero C;
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Apr;22(2):56-67.e16. doi: 10.1016/j.clgc.2023.08.006. Epub 2023 Sep 7.
2024
ASL Città di Torino
AO Cuneo
ASL Asti
ASL Cuneo 2
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Filippi R; Brusa F; Prati V; Vana F; Mennitto A; Maio MD; Buttigliero C; Vignani F; Dionisio R; Icardi M; Guglielmini P; Buosi R; Stevani I; Vormola R; Numico G; Depetris I; Comandone A; Gennari A; Airoldi M; Rossi M; Vellani G; Ortega C; Ruatta F; Tucci M; Pisano C; Turco F; Arnaudo E; Fea E; Vanella P; et alii...
How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists. in Cancer treatment reviews / Cancer Treat Rev. 2024 Apr;125:102692. doi: 10.1016/j.ctrv.2024.102692. Epub 2024 Jan 23.
2024
ASL Asti
Piergiorgio M; Gallieni M; Porta C; Re SGV; Campisi I; Pirovano M; Tucci M; Cosmai L;
2024
ASL Cuneo 2
ASL Asti
Giannatempo P; Polymeropoulos A; Stellato M; Ambrosini P; Gusmaroli E; Cavalli C; Guadalupi V; Claps M; Raggi D; Rametta A; Ortega C; Tucci M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Procopio G; Miceli R; Necchi A;
2024
ASL Cuneo 2
ASL Asti
Stellato M; Giannatempo P; Polymeropoulos A; Guadalupi V; Claps M; Ambrosini P; Raggi D; Rametta A; Cavalli C; Gusmaroli E; Ortega C; Tucci M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Procopio G; Miceli R; Necchi A;
Maximal androgen blockade therapy (MAB) for prostate cancer (PC) and risk of bone fractures: A systematic literature review and meta-analysis in Journal of Clinical Oncology
2024
ASL Asti
Turco F; Saporita I; Calabrese M; Carfi FM; Mogavero A; Treglia G; Gillessen S; Di Maio M; Tucci M; ButtIgliero C; Vogl U;
Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2023 Jan;181:103881. doi: 10.1016/j.critrevonc.2022.103881. Epub 2022 Nov 24
2023
AO Ordine Mauriziano
ASL Asti
AOU San Luigi di Orbassano
Scagliotti GV; Buttigliero C; Di Maio M; Audisio A; Brusa F; Ungaro A; Audisio M; Samuelly A; Turco F; Di Stefano RF; Tucci M; Delcuratolo MD;
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer. in International journal of molecular sciences / Int J Mol Sci. 2023 Dec 20;25(1):78. doi: 10.3390/ijms25010078.
2023
ASL Asti
AOU San Luigi di Orbassano
Farinea G; Poletto S; Carfì FM; Di Stefano RF; Vogl UM; Castro E; Gillessen S; Turco F; Saporita I; Calabrese M; Tucci M; Buttigliero C;
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis. in Tumori / Tumori. 2023 Apr;109(2):233-243. doi: 10.1177/03008916221077144. Epub 2022 Mar 31.
2023
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Buttigliero C; Di Maio M; Scagliotti GV; Ungaro A; Parlagreco E; Audisio A; Audisio M; Angusti T; Parente A; Di Stefano RF; Urban S; Pisano C; Samuelly A; Tucci M; Turco F;
How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy? in Research and reports in urology / Res Rep Urol. 2023 Jan 19;15:9-26. doi: 10.2147/RRU.S350793. eCollection 2023.
2023
ASL Asti
Di Stefano RF; Saporita I; Calabrese M; Cani M; Farinea G; Crespi V; De Filippis M; Poletto S; Pisano C; Di Prima L; Turco F; Tucci M; Buttigliero C;
2088P Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists in Annals of Oncology
2023
ASL Asti
Valsecchi AA; Fusco V; Di Maio M; Santini D; Tucci M; De Giorgi UFF; Dionisio R; Vignani F; Cinieri S;
Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine? in Cells / Cells. 2022 May 11;11(10):1614. doi: 10.3390/cells11101614.
2022
ASL Asti
Tucci M; Cani M; Farinea G; Crespi V; Di Prima L; Di Stefano RF; Parlagreco E; Pisano C; Delcuratolo MD; Turco F; Buttigliero C; Audisio M;
Darolutamide in Metastatic Prostate Cancer. in The New England journal of medicine / N Engl J Med. 2022 Jun 16;386(24):2344. doi: 10.1056/NEJMc2205310.
2022
ASL Asti
Buttigliero C; Turco F; Tucci M;
New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2022 Jun;174:103682. doi: 10.1016/j.critrevonc.2022.103682. Epub 2022 Apr 11
2022
ASL Asti
ASL Torino 4
ASL Cuneo 1
ASL Cuneo 2
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Buttigliero C; Scagliotti GV; Di Maio M; Ortega C; Di Prima L; Audisio A; Turco F; Ungaro A; Parlagreco E; Di Stefano RF; Audisio M; Tucci M;
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond. in Cells / Cells. 2022 Jan 21;11(3):357. doi: 10.3390/cells11030357.
2022
ASL Asti
ASL Torino 4
AOU San Luigi di Orbassano
Tucci M; Di Prima L; Turco F; Di Stefano RF; Ungaro A; Audisio M; Parlagreco E; Delcuratolo MD; Audisio A; Buttigliero C;
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. in Journal for immunotherapy of cancer / J Immunother Cancer. 2022 Jan;10(1):e003697. doi: 10.1136/jitc-2021-003697.
2022
ASL Asti
de Bono J; Zucali PA; Lépine L; Abbadessa G; Loumagne L; Chiron M; Wang R; Dong Y; Lee H; Meng R; Perrino M; Pant S; Shen YC; Gutierrez M; Daniele G; Greystoke A; Saleh M; Su WC; Massard C; Iacovelli R; Bauer TM; Italiano A; Tucci M; Lin CC; Carthon BC;
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. in Journal of clinical pathology / J Clin Pathol. 2022 Jan;75(1):39-44. doi: 10.1136/jclinpath-2020-207089. Epub 2020 Nov 3.
2022
ASL Cuneo 2
ASL Cuneo 1
ASL Asti
Antonelli A; Munari E; Pappagallo G; Iacovelli R; Mosca A; Porta C; Martignoni G; Alongi F; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Rebuzzi SE; Fornarini G; Vellone VG; Bersanelli M; Buti S; Zivi A; et alii...
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. in Cells / Cells. 2022 Feb 25;11(5):803. doi: 10.3390/cells11050803.
2022
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Delcuratolo MD; Ungaro A; Buttigliero C; Di Maio M; Audisio A; Di Prima L; Turco F; Scagliotti GV; Pisano C; Tucci M;
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis. in Current oncology (Toronto, Ont.) / Curr Oncol. 2022 Dec 4;29(12):9511-9524. doi: 10.3390/curroncol29120747.
2022
ASL Asti
Tucci M; Munoz F; Grigolato D; Muraro M; Turco F; Fiorica F; Buttigliero C;
Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study. in Minerva urology and nephrology / Minerva Urol Nephrol. 2022 Dec;74(6):703-713. doi: 10.23736/S2724-6051.22.04701-2. Epub 2022 Feb 11.
2022
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Pisano C; DI Maio M; Tucci M; Scagliotti GV; Samuelly A; DI Stefano RF; Turco F; Bungaro M; Parente A; Buttigliero C; Angusti T;
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy. in Cancer communications (London, England) / Cancer Commun (Lond). 2022 Aug;42(8):683-688. doi: 10.1002/cac2.12340. Epub 2022 Jul 22.
2022
ASL Asti
ASL Cuneo 2
ASL Torino 4
ASL Cuneo 1
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Turco F; Ungaro A; Audisio M; Scagliotti GV; Di Maio M; Delcuratolo MD; Audisio A; Ortega C; Pisano C; Buttigliero C; Di Stefano RF; Tucci M;
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. in Journal of personalized medicine / J Pers Med. 2022 Apr 30;12(5):727. doi: 10.3390/jpm12050727.
2022
ASL Asti
AOU Città della Salute di Torino
ASL Cuneo 1
ASL Cuneo 2
Antonelli A; Porta C; Delahunt B; Giannarini G; Signori A; Banna GL; Rescigno P; Obispo MAL; Bortolus R; Perris R; Scaltriti M; Moch H; Fassan M; Dei Tos AP; Colecchia M; Franco R; Zito-Marino F; Aberasturi Plata Y; Galuppini F; Sbaraglia M; Bollito E; Cossarizza A; Massari F; Salvioni R; Rizzo M; Conti G; Lapini A; Colombo P; Patriarca C; et alii...
1444P Cancer diagnosis communication: The perspective of oncologists, patients and caregivers in Annals of Oncology
2022
ASL Asti
Paratore C; Pacchiana Parravicini MV; Cantale O; Carfì F; Zichi C; Gamba T; Pignataro D; Samuelly A; Tucci M; Di Maio M; Novello S;
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2021 Sep;24(3):812-825. doi: 10.1038/s41391-021-00336-1. Epub 2021 Fe
2021
ASL Asti
ASL Vercelli
AO Ordine Mauriziano
Di Maio M; Scagliotti GV; Gallicchio M; Vignani F; Pisano C; Bungaro M; Samuelly A; Turco F; Tucci M; Di Stefano RF; Buttigliero C;
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Sep;155:127-135. doi: 10.1016/j.ejca.2021.06.034. Epub 2021 Aug 6.
2021
AO Cuneo
ASL Asti
ASL Biella
ASL Cuneo 2
AOU Città della Salute di Torino
ASL Città di Torino
AOU Novara
Tucci M; Baier S; Gennari A; Bellissimo AR; Ciccone G; Masini C; Sacco C; Amoroso D; Montagnani F; Comandone A; Ortega C; Buttigliero C; Fea E; Vanella P; Valcamonico F; Zamparini M; Sirotova Z; Chiappino I; Bianchi S; Mosca A; Dalla Volta A; Prati V; Dal Canton O; Berruti A;
Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results. in Cancers / Cancers (Basel). 2021 Nov 24;13(23):5896. doi: 10.3390/cancers13235896.
2021
ASL Asti
ASL Città di Torino
Tucci M; Comandone T; Vana F; Comandone A;
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients. in Future oncology (London, England) / Future Oncol. 2021 Mar;17(7):807-815. doi: 10.2217/fon-2020-0391. Epub 2021 Jan 29.
2021
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
Cortesi E; Spada M; Salgarello M; Pignata S; Borsatti E; Zichi C; Filice A; Murabito A; Fanti S; Biasco E; Palermo A; Alongi P; Alongi F; Bortolus R; Facchini G; Baldari S; Tucci M; Pinto C; Monari F; Sbrana A; Costa RP; Vincentis G; Caffo O; Frantellizzi V;
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. in Endocrine-related cancer / Endocr Relat Cancer. 2021 Jun 2;28(7):R207-R216. doi: 10.1530/ERC-20-0457.
2021
ASL Asti
ASL Vercelli
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Buttigliero C; Di Maio M; Scagliotti GV; Pisano C; Audisio M; Samuelly A; Bungaro M; Tucci M; Di Stefano RF; Turco F;
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without (223)Ra. in Cancer biotherapy & radiopharmaceuticals / Cancer Biother Radiopharm. 2021 Jun;36(5):391-396. doi: 10.1089/cbr.2020.4442. Epub 2021 Mar 25.
2021
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
De Vincentis G; Cortesi E; Lo Re G; De Giorgi U; Spada M; Salgarello M; Borsatti E; Zichi C; Pignata S; Morabito A; Masini C; Sbrana A; Fanti S; Donner D; Alongi P; Bortolus R; Alongi F; Facchini G; Baldari S; Costa RP; Pinto C; Tucci M; Galli L; Monari F; Caffo O; Frantellizzi V;
Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2021 Jan;157:103185. doi: 10.1016/j.critrevonc.2020.103185. Epub 2020 Nov 27
2021
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
AO Ordine Mauriziano
Buttigliero C; Di Maio M; Scagliotti GV; Di Stefano RF; Turco F; Tucci M; Pisano C;
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):803-814. doi: 10.23736/S2724-6051.21.04186-2. Epub 2021 Mar 29.
2021
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
ASL Torino 4
AO Ordine Mauriziano
Buttigliero C; DI Maio M; Scagliotti GV; Tarenghi F; Vignani F; Bungaro M; Samuelly A; Turco F; DI Stefano RF; Tucci M; Pisano C;
Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report. in Tumori / Tumori. 2021 Dec;107(6):NP149-NP154. doi: 10.1177/03008916211059230. Epub 2021 Nov 11.
2021
ASL Asti
AOU San Luigi di Orbassano
Buttigliero C; Scagliotti GV; Bollito E; Bungaro M; Di Stefano RF; Samuelly A; Tucci M; Turco F;
Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):870-872. doi: 10.23736/S2724-6051.21.04817-5.
2021
ASL Asti
ASL Torino 4
AOU San Luigi di Orbassano
Tucci M; Turco F; Buttigliero C;
COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave? in ESMO open / ESMO Open. 2021 Apr;6(2):100100. doi: 10.1016/j.esmoop.2021.100100. Epub 2021 Mar 19.
2021
ASL Asti
ASL Vercelli
AO Ordine Mauriziano
Cinieri S; Tucci M; Beretta GD; La Verde N; Giuffrida D; Del Mastro L; De Giorgi U; Chiari R; Russo A; Di Maio M; Silvestris N; Perrone F;
Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study in Cancer Research
2021
ASL Asti
Wang R; Loumagne L; De Bono J; Dong Y; Chiron M; Abbadessa G; Lee H; Shen Y-C; Perrino M; Meng R; Gutierrez M; Pant S; Daniele G; Greystoke A; Su W-C; Massard C; Saleh M; Italiano A; Iacovelli R; Carthon B; Bauer TM; Tucci M; Lin C-C; Zucali P;
P45.12 Renal Function Change During Alectinib in ALK Rearranged Non-Small Cell Lung Cancer: A Retrospective Multicentre Analysis in Journal of Thoracic Oncology
2021
ASL Asti
Di Maio M; Tucci M; Novello S; Pignataro D; Paratore C;
2021
ASL Torino 3
ASL Torino 5
ASL Torino 4
ASL VCO
ASL Alessandria
ASL Asti
AOU Città della Salute di Torino
ASL Città di Torino
AOU Alessandria
ASL Biella
Di Maio M; Buffoni L; Traverso E; Tucci M; Fanchini L; Pignataro D; Saggia C; Carnio S; Bustreo S; Buosi R; Vavalà T; Boglione A; Spadi R; Bironzo P;
Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review. in Cancers / Cancers (Basel). 2020 Sep 9;12(9):2568. doi: 10.3390/cancers12092568.
2020
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano
ASL Vercelli
Tucci M; Di Maio M; Necchi A; Gamba T; Buttigliero C; Vignani F; Marandino L;
On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2020 Oct;31(10):1415-1416. doi: 10.1016/j.annonc.2020.06.005. Epub 2020 Jun 18.
2020
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
Zucali P; Tucci M; Verri E; Procopio G; Mucciarini C; Mosca A; Massari F; Fratino L; Masini C; Fornarini G; Ermacora P; Donini M; Buti S; Ceresoli GL; Bortolus R; Berruti A; Baldessari C; Buttigliero C; Zagonel V; Caffo O;
The prognostic value of pain in castration-sensitive prostate cancer. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2020 Dec;23(4):654-660. doi: 10.1038/s41391-020-0255-x. Epub 2020 Jul
2020
ASL Asti
ASL Vercelli
Milella M; Casadei C; Buttigliero C; Maines F; Pierantoni F; Bimbatti D; Mosillo C; Tucci M; De Giorgi U; Caffo O; Ciccarese C; Tortora G; Iacovelli R;
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2020 Aug;152:102994. doi: 10.1016/j.critrevonc.2020.102994. Epub 2020 May 24
2020
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
AO Ordine Mauriziano
Di Maio M; Tucci M; Scagliotti GV; Vignani F; Turco F; Tabbò F; Pisano C; Di Stefano RF; Buttigliero C; Leone G;
2020
ASL Biella
ASL Città di Torino
ASL Asti
AO Cuneo
ASL Cuneo 2
AOU Città della Salute di Torino
Fea E; Buttigliero C; Montagnani F; Comandone A; Gennari A; Tucci M; Chiappino I; Canton OD; Masini C; Sacco† C; Amoroso D; Sirotova Z; Ciccone G; Valcamonico F; Vanella P; Ortega C; Prati V; Bianchi S; Mosca A; Berruti A;
Evaluation of cognitive function (CogF) in trials testing new-generation hormonal treatments (NGHT) in patients with prostate cancer (PC): A systematic review in Annals of Oncology
2020
ASL Asti
Marandino L; Buttigliero C; Vignani F; Gamba T; Necchi A; Tucci M; Di Maio M;
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223) in Journal of Clinical Oncology
2020
ASL Asti
AOU San Luigi di Orbassano
Caffo O; Frantellizzi V; Tucci M; Galli L; Monari F; Baldari S; Masini C; Bortolus R; Facchini G; Alongi P; Zichi C; Biasco E; Fanti S; Pignata S; Filice A; Borsatti E; Rossetti S; Spada M; Cortesi E; De Vincentis G;
Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. in Cancer drug resistance (Alhambra, Calif.) / Cancer Drug Resist. 2020 Sep 12;3(4):726-741. doi: 10.20517/cdr.2020.42. eCollection 2020.
2020
ASL Asti
AOU San Luigi di Orbassano
Tucci M; Buttigliero C; Bungaro M;
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents. in Endocrine / Endocrine. 2019 Jun;64(3):724-726. doi: 10.1007/s12020-019-01947-4. Epub 2019 May 7.
2019
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
Berruti A; Vittorio Scagliotti G; Sigala S; Buttigliero C; Bedussi F; Dalla Volta A; Pia A; Ferrari L; Tucci M; Roca E;
Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): A network meta-analysis of randomized controlled trials (RCT) in Annals of Oncology
2019
ASL Asti
Altavilla A; Maio MD; Tucci M; Lolli C; Schepisi G; Buttigliero C; Vignani F; De Giorgi U;